Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with glucose intolerance, and changes of blood and urine purine compounds.
- Conditions
- glucose intolerance
- Registration Number
- JPRN-UMIN000024316
- Lead Sponsor
- Tsukuba International Clinical Pharmacology Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Not provided
1.Routine user of medicine or supplement. 2.Subject who is currently being treated for diabetes. 3.Subject who has or had renal function disorder. 4.Subject with a history of gout, hyperuricemia or urolithiasis. 5.Subject who has a history of renal disorder. 6.Subject who has or had hypersensitivity, idiosyncracy (allergy) to drug. 7.Subjects taking azathioprine, mercaptopurine or other purine analogs 8.Subject with a disease or a disorder in heart, kidney, pulmonary organ, digestive organ or blood function that are considered to affect absorption, distribution, metabolism or excretion of a drug. 9.Subject who participated in another clinical study for a drug with a new compound within 4 weeks before the administration of drug in the present study. 10.Subject who donated 400 mL of blood within 12 weeks, 200 mL of blood within 4 weeks or blood components within 2 weeks. 11.Subject who used other drugs (including herbs) or supplements within 2 weeks before the administration of drug in this study. 12.Sujbect who plans to take other drugs (including herbs) or supplements before the end of the present study. 13.Subject who was judged not to be appropriate by the principal investigator or sub investigators by other reasons.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method